Drug cost analysis of outpatients with cardiovascular disease under the national health insurance scheme
DOI:
https://doi.org/10.46542/pe.2023.234.14Keywords:
Cardiology, Drug cost, INA-CBG, National Health Insurance (JKN), OutpatientAbstract
Background: Cardiovascular disease is one of the catastrophic diseases that absorbs the most health budgets. Reimbursement of healthcare costs from the National Health Insurance Agency is done through the case-based groups (INA-CBGs) and fee-for-service (non-INA-CBGs) methods based on e-catalogue drug prices. Drug costs are a concern.
Objective: To evaluate drug prescription compliance to the national formulary, total drug cost and drugs cost included in the INA-CBGs package.
Method: This observational study used retrospective prescription data from the outpatient Cardiology Clinic. A quantitative analysis was conducted for prescription compliance with formulary and drug costs.
Result: Out of the 4,443 prescriptions, the prescription alignment with the national formulary was 98%. The difference between the total e-catalogue and the actual drug costs was IDR4,818,252 (0.9%) (p > 0.05). Drug costs constitute 19% of the INA-CBGs package.
Conclusion: Drug prescribing is quite efficient with 98% compliance with the formulary and drug costs constitute 19% of the INA-CBGs package.
References
Aminde, L.N., Dzudie, A., Mapoure, Y.N., Tantchou, J.C. & Veerman, J.L. (2021). Estimation and determinants of direct medical costs of ischaemic heart disease, stroke and hypertensive heart disease: evidence from two major hospitals in Cameroon. BMC Health Services Research, 21(1):1–14 https://doi.org/10.1186/s12913-021-06146-4
Cheng, Q., Asante, A., Susilo, D., Satrya, A., Man, N., Fattah, R.A., Haemmerli, M., Kosen, S., Novitasari, D., Puteri, G.C., Adawiyah, E., Hayen, A., Gilson, L., Mills, A., Tangcharoensathien, V., Jan, S., Thabrany, H. & Wiseman, V. (2022). Equity of health financing in Indonesia: A 5-year financing incidence analysis (2015–2019). The Lancet Regional Health - Western Pacific, 21:100400 https://doi.org/10.1016/j.lanwpc.2022.100400
Ciccarello, C., Leber, M.B., Leonard, M.C., Nesbit, T., Petrovskis, M.G., Pherson, E., Pillen, H.A., Proctor, C. & Reddan, J. (2021). ASHP Guidelines on the Pharmacy and Therapeutics Committee and the Formulary System. American Journal of Health-System Pharmacy: AJHP : Official Journal of the American Society of Health-System Pharmacists, 78(10):907–918 https://doi.org/10.1093/ajhp/zxab080
CMS. (2022). CMS Framework for Health Equity 2022-2032 2 CMS Framework for Health Equity Contents
Hermansyah, A., Sainsbury, E. & Krass, I. (2018). Investigating the impact of the universal healthcare coverage programme on community pharmacy practice. Health and Social Care in the Community, 26(2):e249–e260 https://doi.org/10.1111/hsc.12506
Hermansyah, A., Wulandari, L., Kristina, S.A. & Meilianti, S. (2020). Primary health care policy and vision for community pharmacy and pharmacists in Indonesia. Pharmacy Practice, 18(3):1–12 https://doi.org/10.18549/PharmPract.2020.3.2085
Kim, E., Kwon, H.Y., Baek, S.H., Lee, H., Yoo, B.S., Kang, S.M., Ahn, Y. & Yang, B.M. (2018). Medical costs in patients with heart failure after acute heart failure events: a one-year follow-up study. Journal of Medical Economics, 21(3):288–293 https://doi.org/10.1080/13696998.2017.1403922
Mendrofa, D.E. & Suryawati, C. (2016). Analisis Pengelolaan Obat Pasien BPJS Di Instalasi Farmasi Rumah Sakit Panti Wilasa Citarum Semarang Rumah Sakit Panti Wilasa Citarum memiliki visi dan misi dalam melayani Rumah Sakit Panti Wilasa Citarum melayani. Manajemen Kesehatan Indonesia, 4(3):214–221 https://ejournal.undip.ac.id/index.php/jmki/article/view/13757
MoH. (2008). KMK No. 129 tentang Standar Pelayanan Minimal RS.pdf. In 129
MoH. (2016a). PMK 76 tentang Pedoman Indonesian Case Based Groups (INA CBG’s) dalam Pelaksanaan Jaminan Kesehatan Nasional. Menteri Kesehatan Republik Indonesia, 1–275
MoH. (2016b). The Ministry of Health Regulation Number 52 of 2016 on Health Service Tariff Standards in the Implementation of the Health Insurance Program. http://hukor.kemkes.go.id/upload.pdf
MoH. (2019). Laporan Riskesdas 2018 Nasional.pdf (p. 674)
MoH. (2021). Indonesian Health Profile. In Pusdatin.Kemenkes.Go.Id. Ministry of Health Republic Indonesia https://www.kemkes.go.id/downloads/.pdf
Ramadhan, L., Aritonang, M. & Anggriani, Y. (2021). Analisis Perbedaan Tarif Rumah Sakit dan Tarif INA-CBGs Pelayanan Rawat Jalan di RSUD Pasar Rebo Jakarta. Journal of Islamic Pharmacy, 6(2):73–78 https://doi.org/10.18860/jip.v6i2.12147
Ross, R. & Dutta, A. (2018). Is Indonesia’s National Health Insurance Associated with Greater Hospital Efficiency? Evidence from a Survey of Private Hospitals. Health Policy Plus, 1–8
Rosso, R.J. (2022). U.S. Health Care Coverage and Spending. Congressional Research Service, 1–3 https://crsreports.congress.gov
Shastry, R.I., Ullal Sheetal, D., Sowjanya, Bethi, Y. & Kumar, J.U. (2015). Cost analysis of drugs used in elderly patients with a cardiovascular disorder. Research Journal of Pharmaceutical, Biological and Chemical Sciences, 6(1):83–86
Urbich, M., Globe, G., Pantiri, K., Heisen, M., Bennison, C., Wirtz, H.S. & Di Tanna, G.L. (2020). A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014–2020). PharmacoEconomics, 38(11):1219–1236 https://doi.org/10.1007/s40273-020-00952-0
WHO. (2017). Provider payment methods and strategic purchasing for UHC. 6 http://apps.who.int/iris/bitstream/10665/258894/1/provider_payment_methods_fr_uhc.pdf
WHO. (2021). Cardiovascular diseases (CVDs). World Health Organisation https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
WHO. (2022). Universal health coverage (UHC). World Health Organisation https://www.who.int/news-room/fact-sheets/detail/universal-health-coverage-(uhc)
